Video

Dr. Hwu on the Uptake of Cellular Therapy in Oncology

Author(s):

Patrick Hwu, MD

In Partnership With:

Patrick Hwu, MD, discusses the uptake of cellular therapy in the treatment of patients with cancer.

Patrick Hwu, MD, president, CEO, Moffitt Cancer Center, discusses the uptake of cellular therapy in the treatment of patients with cancer.

The integration of cellular therapy has transformed the treatment paradigms of many oncologic malignancies. Additional research regarding cellular therapy is necessary to continue the growth of their therapeutic modality. Moffitt Cancer Center was a leader in developing and utilizing the CD19-directed CAR T-cell therapy, says Hwu.

Beyond cellular therapy, expanding the use of targeted therapy, as well as cancer-prevention strategies are long-term goals of Moffitt Cancer Center and the oncology field in general, concludes Hwu.

Related Videos
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Alastair Thompson, BSc, MBChB, MD, FRCS
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Related Content
Nausheen Ahmed, MD, MBBS
July 24th 2024

Reduced Incidence of ICANS and CRS After 2 Weeks Post-CAR T Supports Shortened Monitoring Period in DLBCL

Andrew Kuykendall, MD
October 16th 2023

FDA Approval Insights: Momelotinib in Myelofibrosis With Anemia

Richard Kim, MD
July 19th 2024

Exploring Unmet Needs to Optimize Neoadjuvant Therapy in Resectable CRC

Nikhil I. Khushalani, MD; Martin F. Dietrich, MD, PhD; Jason J. Luke, MD, FACP; Vishal A. Patel, MD, FAAD, FACMS
March 6th 2023

CSCC Experts Discuss Considerations for Determining Resectable Disease and Translating Data Into Practice

Francisco Hernandez-Ilizaliturri, MD
July 15th 2024

CAR T-Cell Therapy Selection in Follicular Lymphoma Requires Careful Consideration

The FDA has granted fast track designation to CT-0525 for the treatment of patients with HER2-overexpressing solid tumors.
July 14th 2024

FDA Awards Fast Track Designation to CT-0525 for HER2-Overexpressing Solid Tumors